Surfactant replacement therapy in neonates with respiratory failure due to bacterial sepsis.
We describe four newborns (gestational ages 29-37 weeks; birthweights 1380-3040 grams) who were mechanically ventilated for respiratory insufficiency because of bacterial sepsis. A beneficial effect of bovine surfactant (Alvofact, dosages 50 or 100 mg/kg) was found, as shown by decreases in mean airway pressures and oxygen demands. No side effects were seen after instillation.
Fetter
W P
WP
Department of Pediatrics, Sophia Hospital, Zwolle, The Netherlands.
Baerts
W
W
Bos
A P
AP
van Lingen
R A
RA
D001424:Bacterial Infections / Q000150:complications*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008055:Lipids / Q000627:therapeutic use*; D008297:Male; D010743:Phospholipids; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D012129:Respiratory Function Tests
D008055:Lipids; D010743:Phospholipids; D011663:Pulmonary Surfactants; C078272:SF-RI 1, bovine surfactant preparation